Daiichi Sankyo’s Growth Plan Is Built On ADCs

 
• By Jessica Merrill

The Japanese pharma has established itself as an early leader in antibody-drug conjugates (ADCs) for cancer. Global oncology business head Ken Keller talked to Scrip about the portfolio, pipeline and deals.

growth plan
Daiichi Sankyo is on a solid growth trajectory. • Source: Shutterstock

More from Anticancer

More from Therapy Areas